-
A new benzodiazepine anticonvulsant was recently approved for the treatment of a difficult-to-treat childhood epilepsy (Lennox-Gastaut syndrome [LGS]). Clobazam is manufactured by Catalent Pharma Solutions and marketed as ONFI.
-
Excessive daytime sleepiness appears to be an important risk factor for stroke. It is unknown whether this is related to obstructive sleep apnea or other mechanisms.
-
A meta-analysis demonstrates that earlier nephrologist referral leads to reduced mortality and hospitalization as well as better preparation and dialysis access placement.
-
-
Between statin head-to-head trials are uncommon.
-
The advisory committee on immunization practices (ACIP) of the CDC has updated their recommendations for immunization of health care providers (HCP) against communicable infectious diseases.
-
Insomnia is relatively common and experienced around the world. Estimates have identified prevalence rates ranging from 5-50%.
-
On december 6, 2011, the food and drug administra- tion (FDA) announced that "HCG products marketed as weight loss aids are unproven and illegal."
-
Behavioral therapy works as well as drug treatment for male overactive bladder.
-
